Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting: A Scientific Discussion of Present and Future Capabilities

The purpose of the public workshop is to host a scientific discussion with expert panel members and interested stakeholders about the challenges in using the currently available data and methods for assessing the impact of opioid formulations with abuse-deterrent properties on opioid misuse, abuse, addiction, overdose, and death in the postmarket setting. The goal of this meeting is to discuss ways to improve the analysis and interpretation of existing data, as well as to discuss opportunities and challenges for collecting and/or linking additional data to improve national surveillance and research capabilities in this area.


July 10, 2017 from 8:30 a.m. to 5:00 p.m.
July 11, 2017 from 8:30 a.m. to 5:00 p.m.


Sheraton Silver Spring
8777 Georgia Avenue
Silver Spring, MD 20910
Tel: 301-589-0800

Meeting Materials


Webcast of the Public Workshop:

The archived webcast of the public workshop is available on the link below.

Archived Webcast disclaimer icon


The transcripts of the public workshop are now available below, and accessible online at https://www.regulations.gov/searchResults?rpp=25&po=0&s=FDA-2017-N-2903&fp=true&ns=true.

It may be viewed at the Division of Dockets Management.

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

Comments on the Public Workshop:

Please refer to the Federal Register Notice on instructions for submitting either electronic or written comments on this public workshop. The deadline for comments is September 11, 2017.

For further information contact:

Scientific Contact:
Cynthia Kornegay
Food and Drug Administration
10903 New Hampshire Avenue
Building 22, Room 2456, Silver Spring, MD, 20993-0002
Tel: 301-796-0187, Email: Cynthia.Kornegay@fda.hhs.gov

Logistics Contact:
Cherice Holloway
Food and Drug Administration
10903 New Hampshire Avenue
Building 22, Room 4466, Silver Spring, MD, 20993-0002
Tel: 301-796-4909, Email: Cherice.Holloway@fda.hhs.gov


Page Last Updated: 11/07/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English